These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 8702308)
1. Rationale of lymph node dissection for breast cancer--from the viewpoint of analysis of axillary lymphatic flow using activated carbon particle CH40. Sawai K; Hagiwara A; Shimotsuma M; Sakakibara T; Imanishi T; Takemoto Y; Takahashi T Gan To Kagaku Ryoho; 1996 Mar; 23 Suppl 1():30-5. PubMed ID: 8702308 [TBL] [Abstract][Full Text] [Related]
2. Lymph-node staining with activated carbon CH40: a new method for axillary lymph-node dissection in breast cancer. Yokota T; Saito T; Narushima Y; Iwamoto K; Iizuka M; Hagiwara A; Sawai K; Kikuchi S; Kunii Y; Yamauchi H Can J Surg; 2000 Jun; 43(3):191-6. PubMed ID: 10851412 [TBL] [Abstract][Full Text] [Related]
3. [Visualising lymph nodes by aclarubicin bound to activated carbon particles in breast cancer surgery]. Imanishi T; Hagiwara A; Sawai K; Yamaguchi T; Sakakura C; Shirasu M; Ohgaki M; Yamasaki J; Togawa T; Takahashi T Gan To Kagaku Ryoho; 1997 Sep; 24(12):1796-8. PubMed ID: 9382535 [TBL] [Abstract][Full Text] [Related]
4. Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer. Petrik DW; McCready DR; Sawka CA; Goel V J Surg Oncol; 2003 Feb; 82(2):84-90. PubMed ID: 12561062 [TBL] [Abstract][Full Text] [Related]
5. [Breast cancer: the significance of parasternal node dissection, with reference to the lymph flow of the breast]. Nakazawa T; Kohno N; Yamamoto K; Imanaka Y; Euruya Y; Motomura K; Wakita K; Fujiwara O; Saitoh Y Gan No Rinsho; 1988 Jul; 34(8):969-75. PubMed ID: 3404659 [TBL] [Abstract][Full Text] [Related]
6. [Management of the axilla in breast cancer: evidences and unresolved issues]. Fodor J; Polgár C; Péley G; Németh G Orv Hetil; 2001 Sep; 142(36):1941-50. PubMed ID: 11680099 [TBL] [Abstract][Full Text] [Related]
7. [Drug concentration in axillary lymph nodes of patients with breast cancer after lymphatic chemotherapy]. Chen JH; Yang YM; Li KZ; Ling R; Yao Q; Yang H Ai Zheng; 2005 Apr; 24(4):494-7. PubMed ID: 15820077 [TBL] [Abstract][Full Text] [Related]
8. The impact of axillary lymph nodes removed in staging of node-positive breast carcinoma. Kuru B; Bozgul M Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1328-34. PubMed ID: 16997505 [TBL] [Abstract][Full Text] [Related]
9. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients. Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881 [TBL] [Abstract][Full Text] [Related]
10. Predictors of non-sentinel lymph node metastasis in breast cancer patients. Goyal A; Douglas-Jones A; Newcombe RG; Mansel RE; Eur J Cancer; 2004 Jul; 40(11):1731-7. PubMed ID: 15251163 [TBL] [Abstract][Full Text] [Related]
11. Lymphatic mapping and sentinel lymphadenectomy in early stage breast carcinoma. Altinyollar H; Kapucuoglu N; Pak I; Berberoglu U J Exp Clin Cancer Res; 2000 Jun; 19(2):141-4. PubMed ID: 10965808 [TBL] [Abstract][Full Text] [Related]
12. Nonsentinel lymph node status after positive sentinel lymph node biopsy in early breast cancer. Saidi RF; Dudrick PS; Remine SG; Mittal VK Am Surg; 2004 Feb; 70(2):101-5; discussion 105. PubMed ID: 15011910 [TBL] [Abstract][Full Text] [Related]
13. Axillary and extra-axillary lymph node recurrences after a tumor-negative sentinel node biopsy for breast cancer using intralesional tracer administration. van der Ploeg IM; Kroon BB; Antonini N; Valdés Olmos RA; Rutgers EJ; Nieweg OE Ann Surg Oncol; 2008 Apr; 15(4):1025-31. PubMed ID: 18219534 [TBL] [Abstract][Full Text] [Related]
14. Is sentinel lymph node biopsy more accurate than axillary dissection for staging nodal involvement in breast cancer patients? Marrazzo A; Taormina P; Gebbiab V; David M; Riili I; Lo Gerfo D; Casà L; Noto A Chir Ital; 2007; 59(5):693-9. PubMed ID: 18019642 [TBL] [Abstract][Full Text] [Related]
15. Lymph nodes in the tail of the breast can be missed in standard axillary dissection. Williams RN; Jones L; Stotter A Eur J Surg Oncol; 2009 Mar; 35(3):271-5. PubMed ID: 18407454 [TBL] [Abstract][Full Text] [Related]
16. [Exploration of the extent of axillary dissection for patients with node positive primary breast cancer]. Ouyang T; Li JF; Wang TF; Lin BY Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(5):298-300. PubMed ID: 15842936 [TBL] [Abstract][Full Text] [Related]
17. Sentinel lymphadenectomy for breast cancer in a community managed care setting. Guenther JM; Krishnamoorthy M; Tan LR Cancer J Sci Am; 1997; 3(6):336-40. PubMed ID: 9403045 [TBL] [Abstract][Full Text] [Related]
18. Determinants of axillary recurrence after axillary lymph node dissection for invasive breast cancer. Voogd AC; de Boer R; van der Sangen MJ; Roumen RM; Rutten HJ; Coebergh JW Eur J Surg Oncol; 2001 Apr; 27(3):250-5. PubMed ID: 11373100 [TBL] [Abstract][Full Text] [Related]
19. [Identification of the sentinel node in patients with breast carcinoma]. Nieweg OE; Kapteijn BA; Peterse JL; Rutgers EJ; van Dongen JA; Kroon BB Ned Tijdschr Geneeskd; 1996 Nov; 140(45):2235-9. PubMed ID: 8984369 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions. White RE; Vezeridis MP; Konstadoulakis M; Cole BF; Wanebo HJ; Bland KI J Am Coll Surg; 1996 Dec; 183(6):575-82. PubMed ID: 8957459 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]